论文部分内容阅读
采用乳化离子交联法制备虫草素羧甲基壳聚糖纳米粒(1-CMC-NPs)。通过单因素试验和正交设计,以粒径和包封率为指标优化处方组成。结果表明,优化后1-CMC-NPs的包封率和载药量约为70%和9%,平均粒径约为148 nm,?电位约为-25 m V,外观呈球形或类球形。差示扫描量热(DSC)和X射线衍射(XRD)分析结果提示纳米粒中药物可能以无定形存在。体外释放试验中,1-CMC-NPs在不含及含血清的磷酸盐缓冲液(p H 7.4)中,48 h累积释放率为68.1%和80.4%,与其溶液相比,呈现明显的缓释效果。
Cordycepin carboxymethyl chitosan nanoparticles (1-CMC-NPs) were prepared by emulsion ionic crosslinking. Through single factor experiment and orthogonal design, the particle size and entrapment efficiency were taken as indexes to optimize the prescription composition. The results showed that the encapsulation efficiency and drug loading of 1-CMC-NPs were about 70% and 9%, respectively. The average particle diameter was about 148 nm and the potential was about -25 mV. The appearance of the nanoparticles was spherical or spheroidal. Differential Scanning Calorimetry (DSC) and X-ray Diffraction (XRD) results suggest that the drug in the nanoparticle may be amorphous. In vitro release assay, the cumulative release rates of 1-CMC-NPs were 68.1% and 80.4% in PBS-free and serum-free phosphate buffer (p H 7.4) effect.